Age and histologic diagnosis to intermediate risk prostate cancer prior to radical prostatectomy
Item
1. men 18 years or older with a histologic diagnosis of low to intermediate risk prostate cancer prior to radical prostatectomy as defined by:
boolean
C0001779 (UMLS CUI [1])
C0033578 (UMLS CUI [2,1])
C0344441 (UMLS CUI [2,2])
C0035648 (UMLS CUI [2,3])
C0332152 (UMLS CUI [3,1])
C0194810 (UMLS CUI [3,2])
Clinical Stage
Item
1. clinical stage t1-t2b
boolean
C1300072 (UMLS CUI [1])
PSA measurement
Item
2. psa < 20
boolean
C0201544 (UMLS CUI [1])
Gleason score
Item
3. gleason score < 7
boolean
C0332326 (UMLS CUI [1])
Prognostic Factors
Item
patients who have more than one of the following prognostic factors: t2b, gleason 7, psa 10-20 are not eligible.
boolean
C1514474 (UMLS CUI [1,1])
C1300072 (UMLS CUI [1,2])
C1514474 (UMLS CUI [2,1])
C0332326 (UMLS CUI [2,2])
C1514474 (UMLS CUI [3,1])
C0138741 (UMLS CUI [3,2])
Surgically resectable as determined by a urologic evaluation
Item
2. patient's tumor must be considered surgically resectable as determined by a urologic evaluation
boolean
C0543467 (UMLS CUI [1,1])
C0031809 (UMLS CUI [1,2])
C0042077 (UMLS CUI [1,3])
Ecog performance status
Item
3. ecog performance status of 0-1
boolean
C1520224 (UMLS CUI [1])
Life expectancy
Item
4. life expectancy greater than 2 years
boolean
C0023671 (UMLS CUI [1])
Informed consent
Item
5. able to understand and give informed consent
boolean
C0021430 (UMLS CUI [1])
Compliance behavior concomitant medications
Item
6. patients must agree not to take dietary phytoestrogens or other estrogen containing supplements
boolean
C1321605 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
Locally adcanced or high-risk disease
Item
1. patients with locally advanced or high-risk disease as defined above.
boolean
C0677984 (UMLS CUI [1])
C0475283 (UMLS CUI [2])
Testosterone Measurement
Item
2. patients who have a testosterone less than 280 ng/dl.
boolean
C0523912 (UMLS CUI [1])
Comorbidities
Item
3. patients who have evidence of cerebrovascular accident or ischemia, recent deep venous thrombosis, pulmonary emboli, unstable angina or clinical congestive heart failure.
boolean
C0009488 (UMLS CUI [1,1])
C0038454 (UMLS CUI [1,2])
C0009488 (UMLS CUI [2,1])
C0917798 (UMLS CUI [2,2])
C0009488 (UMLS CUI [3,1])
C0332185 (UMLS CUI [3,2])
C0149871 (UMLS CUI [3,3])
C0009488 (UMLS CUI [4,1])
C0034065 (UMLS CUI [4,2])
C0009488 (UMLS CUI [5,1])
C0002965 (UMLS CUI [5,2])
C0009488 (UMLS CUI [6,1])
C0018802 (UMLS CUI [6,2])
Investigational therapy
Item
4. patients who are receiving any other investigational therapy.
boolean
C2348568 (UMLS CUI [1])
Active serious Infection and Comorbidity
Item
5. patients with an active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment.
boolean
C0009450 (UMLS CUI [1])
C0009488 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
Limited ability to give informed consent
Item
6. dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
Immunodeficiency or oral corticosteroids
Item
7. patients with immunodeficiency or on oral corticosteroids
boolean
C0021051 (UMLS CUI [1])
C0239126 (UMLS CUI [2])
Histologic evidence of small cell carcinoma of the prostate
Item
8. histologic evidence of small cell carcinoma of the prostate.
boolean
C0262584 (UMLS CUI [1,1])
C0033572 (UMLS CUI [1,2])
C0344441 (UMLS CUI [1,3])
Patients with a prior history of myocardial infarction, pulmonary embolism, cva or atrial fibrillation
Item
9. patients with a prior history of myocardial infarction, pulmonary embolism, cva or atrial fibrillation.
boolean
C0262926 (UMLS CUI [1,1])
C0027051 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0034065 (UMLS CUI [2,2])
C0262926 (UMLS CUI [3,1])
C0038454 (UMLS CUI [3,2])
C0262926 (UMLS CUI [4,1])
C0004238 (UMLS CUI [4,2])
Patients with active thrombophlebitis
Item
10. patients with active thrombophlebitis.
boolean
C0040046 (UMLS CUI [1])
Vasidilator responsive angina pectoris
Item
11. patients with evidence of active angina as evidenced by chest pain responsive to nitroglycerin or other anginal equivalent.
boolean
C0002962 (UMLS CUI [1,1])
C0205342 (UMLS CUI [1,2])
C0042402 (UMLS CUI [1,3])
medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained
Item
12. medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained
boolean
C0009488 (UMLS CUI [1,1])
C1113679 (UMLS CUI [1,2])
C0009488 (UMLS CUI [2,1])
C0242568 (UMLS CUI [2,2])
Active therpy for other neoplastic disorders
Item
13. patients who are currently receiving active therapy for other neoplastic disorders will not be eligible for study.
boolean
C0085183 (UMLS CUI [1,1])
C0597030 (UMLS CUI [1,2])
Ongoing medication
Item
14. patients taking any of the following medications who cannot discontinue these medications for three weeks during administration of androgen deprivation: aprepitant, bexarotene, clarithromycin, itraconazole, ketoconazole, st. john's wort.
boolean
C2826666 (UMLS CUI [1,1])
C1176306 (UMLS CUI [1,2])
C2826666 (UMLS CUI [2,1])
C0765273 (UMLS CUI [2,2])
C2826666 (UMLS CUI [3,1])
C0055856 (UMLS CUI [3,2])
C2826666 (UMLS CUI [4,1])
C0064113 (UMLS CUI [4,2])
C2826666 (UMLS CUI [5,1])
C0022625 (UMLS CUI [5,2])
C2826666 (UMLS CUI [6,1])
C0936242 (UMLS CUI [6,2])